Merck's PCSK9 Pill Shows Promise in Lowering LDL Cholesterol
TL;DR Summary
Merck's oral PCSK9 inhibitor, Enlicitide, significantly reduces LDL cholesterol by up to 60% in high-risk patients already on statins, matching the efficacy of injectable treatments, according to a late-stage clinical trial.
- Merck’s pill to reduce cholesterol on top of statins matches results from injectables statnews.com
- Merck PCSK9 Pill Results Point to Extremely Low Cholesterol Future The New York Times
- Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial Yahoo Finance
- Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds CNN
- Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol AJMC
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
86%
226 → 31 words
Want the full story? Read the original article
Read on statnews.com